Focus on breast cancer  by Baselga, Jose & Norton, Larry
F O C U S
CANCER CELL : MAY 2002 · VOL. 1 · COPYRIGHT © 2002 CELL PRESS 319
Focus on breast cancer
Jose Baselga1,3 and Larry Norton2
1Vall dHebron University Hospital and Universidad Autonoma de Barcelona, 08035 Barcelona, Spain
2Memorial Sloan-Kettering Cancer Center, New York, New York 10021
3Correspondence: baselga@hg.vhebron.es
Epidemiology, incidence rates, and risk factors
Breast cancer is the most frequent malignancy among women
in Western countries, with an incidence rate in the U.S. of 111
cases per 100,000 woman-years (wy) and a mortality rate of 24
deaths per 100,000 wy (Howe et al., 2001). There are an esti-
mated 1 million new cases per year in the world, with up to 5-
fold lower incidence in Eastern Asia than in Western countries,
a variation probably related to environmental rather than genet-
ic factors (Probst-Hensch et al., 2000). Established risk factors
for breast cancer include:
• Age. Breast cancer incidence rates double about every 10
years, reaching an incidence of 500 cases per 100,000 wy
at age 70.
• Increased hormone exposure, with early menarche, late
menopause, alcohol consumption, postmenopausal obesi-
ty, and hormonal replacement therapy being associated
with increased risk, and young age at first pregnancy, pro-
longed lactation, and physical exercise being associated
with a reduced risk (Feigelson and Henderson, 2001).
• Family history of breast cancer. Risk ratios increase with
increasing numbers of affected first-degree relatives.
Breast cancer incidence rates peaked in the late eighties,
and have been stable thereafter. On the other hand, mortality
has been decreasing, with an encouraging 3.4% annual
decrease from 1995 through 1998 (Howe et al., 2001; Peto et
al., 2000). This decrease in mortality may be the result of wide-
spread mammography screening and the implementation of
adjuvant therapy with tamoxifen and polychemotherapy (EBCT,
1998a, 1998b).
Conventional diagnostics and therapeutics
Breast cancer is an heterogeneous disease, and its clinical
signs and symptoms depend largely on whether the disease is
confined to the breast or has metastasized to adjacent or dis-
tant parts of the body. Frequent sites of metastasis include the
skin, lymph nodes, contralateral breast, bones, lungs, liver, and
the central nervous system. The evaluation of a breast cancer
patient at the time of initial presentation includes a pathological
examination of the tumor and an evaluation of the extent of dis-
ease.The pathological examination includes assessment of his-
tologic type and grade, tumor size, axillary lymph nodes status,
and hormone receptor and ErbB2 receptor status. The evalua-
tion of the extent of disease—or clinical staging—requires a
physical exam and, if clinically indicated, a selected utilization of
imaging techniques ranging from conventional roentograms of
the chest, abdominal sonograms, and bone radionuclide scans
to more complex computed tomography (CT) scans, magnetic
resonance imaging (MRI), and functional imaging such as
positron emission tomography (PET). Extensive utilization of
imaging techniques for initial staging and follow-up is not indi-
cated since it does not improve survival. The extension of the
disease is documented with the TNM staging system, in which T
refers to the tumor, N to nodes and M to metastases (AJCC,
1997). This clinical staging system, ranging from stage I (early
and localized) to stage IV (metastatic) disease, is utilized to
estimate the prognosis and to select the treatment for individual
patients as well as to compare the results from different treat-
ment programs.
The primary therapy of localized—early stage I and II—
breast cancer is either breast-conserving surgery and radiation
therapy or mastectomy with or without reconstruction. Systemic
adjuvant therapies designed to eradicate clinically undetectable
microscopic deposits of cancer cells that may have spread from
the primary tumor result in decreased recurrences and
improved survival (EBCT, 1998a, 1998b). Adjuvant therapies
include chemotherapy and hormonal therapy. Chemotherapy is
usually given for 4 to 6 months in combination with different
agents (polychemotherapy); the drugs most frequently used are
alkylating agents (cyclophosphamide), anthracyclins (doxoru-
bicin), antimetabolites (5-fluorouracil), and antimicrotubule
agents (such as paclitaxel and docetaxel) (Norton, 2001).
Adjuvant hormonal therapy with tamoxifen is beneficial in
patients whose tumors express estrogen and/or progesterone
receptors (EBCT, 1998a). In addition, adjuvant radiation therapy
provides a better local control and may enhance survival
(EBCT, 2000).
In advanced disease, in addition to the agents used in the
adjuvant setting, new active cytotoxic agents include vinca alka-
loids (vinorelbine), pyrimidine analogs (gemcitabine), and new
antimetabolites (capecitabine) (Hortobagyi, 2000). In the hor-
monal therapy front, tamoxifen is a selective estrogen receptor
modulator (SERM) that binds to the estrogen receptor and has
antiestrogenic activity in the breast and estrogenic-like activity
in the endometrium, bone, and lipid metabolism (Jordan, 2001).
New SERMs with a more desirable tissue selectivity are being
evaluated, as well as pure antiestrogens that result in pro-
grammed early receptor destruction (Jordan, 2001). Aromatase
inhibitors that prevent the peripheral tissue conversion of adren-
al androgens into estrogen have recently been shown to be
superior to tamoxifen and are being incorporated into first line
therapy of advanced disease (Nabholtz et al., 2000).
Key genes and pathways involved in the pathogenesis of
breast cancer
Breast cancer results from genetic and environmental factors
leading to the accumulation of mutations in essential genes.
Genes involved in the hereditary and familial forms of breast
cancer include BRCA1, BRCA2, P53, PTEN, and STK11/LKB1
(Nathanson et al., 2001).The 2 BRCA genes appear to serve as
important regulators of cell-cycle “checkpoint control” mecha-
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nisms, involving cell-cycle arrest, apoptosis, and DNA repair.
However, germline mutations of BRCA1 and BRCA2 and of
these other genes account for only 15%–20% of breast cancer
that clusters in families and less than 5% of breast cancer over-
all, and it is likely that breast cancer susceptibility may be dictat-
ed by a larger number of low penetrance mutations.
The most common genetic abnormalities in the progression
of both sporadic and familial breast cancers are losses of het-
erozygosity (LOH) at multiple loci resulting in the uncovering of
the functional consequences of mutations in alleles of tumor
suppressor genes. In addition to the mentioned BRCA and P53
genes, LOH on 13q, 9p, and 16q are known to involve the Rb
(retinoblastoma gene), CDKN2 (encoding the p16 protein), and
CDH1 (encoding the E-cadherin protein), respectively (Dickson
and Lippman, 2001). The second most common type of cytoge-
netic alteration is the amplification of genes, such as ErB2, c-
myc, and cyclin D1 (Dickson and Lippman, 2001).
The role of certain receptors in breast cancer has been
extensively studied, since they are either established or poten-
tial targets for therapy. The estrogen receptors are nuclear
receptors that modulate transcription of target genes that play a
role in the onset and progression of disease; coactivating and
corepressive proteins interact with these receptors and play a
critical role in the initiation of transcription (Elledge and Fuqua,
2000). Activation of tyrosine kinase receptors does also result in
malignant transformation and tumor proliferation. Good exam-
ples of tyrosine kinase receptors in breast cancer are the epi-
dermal growth factor (EGF) family of growth factors receptors,
including the ErbB2 receptor, and the insulin-like growth factors
and their receptors (Dickson and Lippman, 2001).
Early detection and advances in breast cancer imaging
Early detection of breast cancer is a clear priority since cure
rates are greater the earlier the clinical stage at diagnosis.
Screening mammography, despite an ongoing debate (Olsen
and Gotzsche, 2001), is currently the best available tool for
early detection, and reduces breast cancer mortality rates by
about 16% for women 40–49 years old and 25%–30% for
women 50–69 years old (Kerlikowske, 1997). New directions
include the development of improved imaging techniques such
as digital mammography and MRI. MRI
may be more accurate than mammogra-
phy in breast cancer surveillance of
women with a hereditary risk of breast
cancer (Stoutjesdijk et al., 2001). PET
scanning is a functional imaging tech-
nique based on the enhanced glucose
consumption by malignant cells. 18F-
deoxyglucose is given intravenously and
is taken up preferentially by the tumor,
allowing the accurate characterization of primary tumors and
axillary and mediastinal lymph nodes, and also the detection of
distant metastases, all in a single whole-body examination
(Czernin and Phelps, 2001). PET scanning also seems well-
suited to predict therapy outcome in patients with locally
advanced breast cancer (Czernin and Phelps, 2001).
Advances in breast classification
The current pathologic classification and staging system are
suboptimal, since patients with identical tumor types and stage
of disease have markedly different responses to therapy and
overall outcomes. The limitations of the current system stem
from its inability to take into account biological determinants of
prognosis. As a result, many patients who would have been
cured by surgery and radiation therapy alone will receive unnec-
essary cytototoxic therapy. Over the last two decades, the rou-
tine determination of estrogen receptor and other key proteins
such as ErbB2 has provided evidence that breast cancer repre-
sents several distinct subtypes (Figure 1). The advent of
microarray technology with high throughput and parallel analy-
sis of thousands of genes is allowing the linking of expression
profiles to clinical outcome and response to therapy (van’t Veer
et al., 2002); if the predictive value of functional genomics is
confirmed, it will be possible to accurately predict which tumors
will relapse and to choose therapy accordingly (Ince and
Weinberg, 2002). Another important implication is that molecu-
lar profiling may lead to the identification of new targets for ther-
apy.
Recent advances in breast cancer therapy
The majority of cytotoxic agents were developed solely on the
basis of their preclinical activity. However, an increased knowl-
edge of their mechanism(s) of action is allowing the develop-
ment of improved cytotoxic agents. As an example, doxorubicin
inhibits topoisomerase functions, and more specific topoiso-
merase inhibitors are being developed; the stimulation by tax-
anes of tubulin polymerization has lead to the identification in
tubulin polymerization screens of epothilones, active agents on
taxane-refractory breast cancer (Gibbs, 2000).
In parallel, agents against a series of molecular targets that
Figure 1. Evolution in breast cancer classifica-
tion
The classical morphological evaluation of a
breast tumor results in determination of the
tumors histological type and grade, tumor size,
and number of involved axillary lymph nodes. In
the last two decades, biomarkers such as hor-
mone receptors and ErbB2 have been incorpo-
rated as prognostic and predictive factors. A
third evolutionary modification may be under-
way with high throughput microarray technolo-
gy allowing for a comprehensive molecular pro-
filing of tumors.
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dictate malignant growth are being developed. This approach is
illustrated by agents directed at the EGF receptor family of
growth factor receptors (Figure 2). Trastuzumab, a humanized
monoclonal antibody directed at the ErbB2 receptor, is the first
of this new class of agents, and is active and improves survival
in patients with ErbB2 amplification (Slamon et al., 2001). Small
molecules that inhibit receptor kinase activation have shown tol-
erability at doses that fully inhibit receptor function in vivo
(Albanell et al., 2002). These agents are active in preclinical
breast cancer models, and phase II clinical trials in breast can-
cer are ongoing.
Downstream substrates of cell surface receptors being
explored as targets for therapy include the members of the Ras-
Raf-MAP-kinase pathway, involved in cell proliferation, and the
phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway that
plays an important role in survival (Figure 2). Clinical responses
in breast cancer have been observed with anti-RAS agents and
with mTOR inhibitors. Agents are also being developed against
apoptosis-regulating pathways, such as BCL-2 antisense
oligonucleotides (Chen et al., 2000), proteasome inhibitors
(Adams et al., 1999), and inhibitors of cyclin-dependent kinases
(Senderowicz, 2000). Interactions between breast cancer cells
and their surrounding environment are determinant for breast
cancer progression, as exemplified by the tumor’s requirement
for sustained angiogenesis. Antiangiogenic agents include
monoclonal antibodies targeting the vascular endothelial
growth factor (VEGF), its receptors (anti-Flk-1 antibodies), and
receptor tyrosine kinase inhibitors. Clinical responses in
advanced breast cancer have been documented with anti-
VEGF antibodies (Sledge et al., 2000).
It may be oversimplistic to expect that interfering with a single
molecular target may reverse a malignant phenotype that is the
result of the accumulation of multiple successive genetic events.
Thus, identification of the several key drivers in a given tumor will
hopefully lead to individualized treatment in which several target-
ed agents will be combined—tailored combination polytargeted
therapy—in a rational way, rather the current empiric administra-
tion of combination polychemotherapy. In addition, as with
trastuzumab and paclitaxel (Baselga et al., 1998; Slamon et al.,
2001), it is expected that molecular targeting agents and cytotox-
ic agents will be given together in a successful partnership.
Prevention
Significant advances have been made in the field of breast can-
cer prevention in patients with increased risk. Studies with two
different SERMs, tamoxifen and raloxifen, have demonstrated
reductions in breast cancer close to 50%. (Cummings et al.,
1999; Fisher et al., 1998). For women with germline BRCA1 and
BRCA2 mutations, current management guidelines appear to
reduce the risk of breast and ovarian cancer by at least 60%
and 90%, respectively (Eisen et al., 2000). In a similar fashion, it
is anticipated that further advances in the identification of
patients with enhanced breast cancer susceptibility will allow
the successful implementation of prevention strategies.
Challenges for the future
In the last two decades, major advances have been made in our
understanding and treatment of breast cancer that have result-
ed in a decline in breast cancer mortality. To accelerate this
process, research efforts need to be directed to a series of
areas, including breast cancer genetics and study of popula-
tions at risk for genetic predisposition, identification of new tar-
gets for therapy and drug development programs, molecular
profiling of breast tumors, and finally, improved screening and
better diagnostic tools to facilitate early detection and preven-
tion programs. However, for these advances to translate into
benefit for patients, strategies to accelerate their clinical applic-
ability have to be promoted.
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